SanBio (4592 JP): FY27 Guidance Reiterated, All Eyes On How Akuugo Sales Fall Through
SanBio's R&D expenses decreased. H1FY27 Net loss narrowed. Guidance was reiterated. We feel FY27 would be an inflection point for SanBio, but it...
97 Views
Primer: SanBio Co Ltd (4592 JP) - Aug 2026
SanBio is a clinical-stage biotechnology company at a critical inflection point, with its future success hinging on its lead product, SB623...
91 Views
SanBio (4592 JP): Q1 Losses Narrow, NHI Price Listing and Akuugo Launch Done, Guidance Reiterated
SanBio reported lower loss in Q1FY27 on R&D expenses decreased and forex gains. Akuugo received NHI price listing and was eventually launched....
113 Views
SanBio Co Ltd (4592 JP): Q1 FY01/27 flash update
In Q1 FY01/27, the company reported no operating revenue, with an operating loss of JPY953mn and a net loss of JPY836mn. Non-operating income...
118 Views
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views